Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0222 • ACR Convergence 2020
tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis
Diederik De Cock¹, Patrick Durez², Dirk Elewaut³, Bernard Lauwerys⁴, Rene Westhovens⁵ and Patrick Verschueren⁶, ¹KU Leuven, Leuven, Belgium, ²Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ³Ghent University and VIB, Heusden, Belgium, ⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁵University Hospitals Leuven, Belgium, Leuven, Belgium, ⁶University Hospital Leuven, Leuven, Belgium
Background/Purpose: The Tool for Administrative Reimbursement Drug Information Sharing (TARDIS) is an electronic platform combining the collection of data from all Belgian patients with Rheumatoid…
Abstract Number: 0239 • ACR Convergence 2020
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
Christina Charles-Schoeman¹, Sang-Cheol Bae², Arvind Chopra³, Stanley Cohen⁴, Jeffrey R Curtis⁵, Jacques-Eric Gottenberg⁶, Edward C Keystone⁷, Kunihiro Yamaoka⁸, Peter Nash⁹, J-Abraham Simon-Campos¹⁰, William Stohl¹¹, Michael Weinblatt¹², Rene Westhovens¹³, Jeff Siegel¹⁴, Iyabode Tiamiyu¹⁴, Lei Ye¹⁴, Deyuan Jiang¹⁴, Franziska Matzkies¹⁴, Angelika Jahreis¹⁴, John S. Sundy¹⁴ and Jon Giles¹⁵, ¹University of California, Los Angeles, Los Angeles, CA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Center for Rheumatic Diseases, Pune, India, ⁴University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia, ¹⁰Köhler & Milstein Research, Mérida, Mexico, ¹¹University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁴Gilead Sciences, Inc., Foster City, CA, ¹⁵Columbia University, New York, NY
Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and…
Abstract Number: 0483 • ACR Convergence 2020
Can a Clinical Disease Activity Index Based on Patient-Reported Joint Counts (PT-CDAI) Be Used to Inform Target-Based Care in Telemedicine? An Analysis of 2 Early RA Cohort Studies
Caroline Benson¹, Marie-France Valois², Orit Schieir³, Gregory Vitone¹, Aidan Tirpack¹, Michelle Jones⁴, Louis Bessette⁵, Gilles Boire⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Edward C Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Susan Bartlett², Clifton Bingham III¹², Vivian Bykerk¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹³, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Montreal, Canada, ³Canadian Early Arthritis Cohort Study, Montreal, Canada, ⁴Johns Hopkins Arthritis Center, Baltimore, MD, ⁵Laval University, Quebec, Canada, ⁶Universite de Sherbrooke, Sherbrooke, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: COVID-19 mitigation strategies have forced rheumatologists to shift from in-person clinical visits to telemedicine, limiting their ability to carry out complete joint exams needed…
Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Guy Cozzi¹, Pavlo Kyrychenko², Michele Hamburger³ and Elisea Avalos-Reyes⁴, ¹CVS Health, Northbrook, IL, ²CVS Health, Norhtbrook, IL, ³Frances Hamburger Institute, Hauppauge, NY, ⁴CVS Health, Irving, TX
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…
Abstract Number: 0748 • ACR Convergence 2020
Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
Andreas Kerschbaumer¹, Gabriela Supp², Farideh Alasti¹, Josef Smolen² and Daniel Aletaha¹, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is…
Abstract Number: 0765 • ACR Convergence 2020
High Disease Activity at Baseline and Seropositivity Are Associated with Treatment Response at One Year Post Synovial Biopsy in RA Patients
Kieran Murray¹, Candice Low², Francis Young³, Monika Biniecka⁴, Eimear Mylod⁴, Ursula Fearon⁵ and Douglas Veale⁶, ¹Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ²EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ³Saint Vincent's University Hospital, Dublin 4, ⁴Saint Vincent's University Hospital, Dublin 4, Ireland, ⁵Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Despite recent therapeutic advances, our ability to predict prognosis and therapeutic response in RA remains imprecise. This study examines for biomarkers predictive of outcome…
Abstract Number: 0782 • ACR Convergence 2020
Epigenetic Regulation of Metabolic Transporters in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Brian Pedersen¹, Rizi Ai¹, Alyssa Torres¹, Wei Wang¹, Gary Firestein² and Monica Guma³, ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla, CA, ³Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Epigenetic changes contribute to the pathogenesis of rheumatoid arthritis (RA) and a comprehensive epigenomic characterization of RA fibroblast-like synoviocytes (FLS) has recently been described.…
Abstract Number: 0799 • ACR Convergence 2020
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
Renske Hebing¹, Wouter Bos¹, Mike Nurmohamed² and Bart van den Bemt³, ¹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. Electronic Monitoring Feedback (EMF) to improve adherence has…
Abstract Number: 0815 • ACR Convergence 2020
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
Deepan Dalal¹, Tingting Zhang², Hiren Varma² and Theresa Shireman², ¹Brown University, East Providence, RI, ²Brown University, Providence, RI
Background/Purpose: Methotrexate is the preferred initial drug for treatment of rheumatoid arthritis (RA) per American College of Rheumatology guidelines (2015). People with elderly-onset RA, classified as onset…
Abstract Number: 0832 • ACR Convergence 2020
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Eugen Feist¹, Peer-Malte Aries², Silke Zinke³, Harald Burkhardt⁴, Inka Albrecht⁵, Oliver Bley⁵, Michael Obermeier⁶, Patrizia Sternad⁷, Martin Welcker⁷, Cornelia Kühne⁸, Ann-Dörthe Holst⁹, Niklas Thomas Baerlecken¹⁰ and Hans-Peter Tony¹¹, ¹Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ²Rheumatologie im Struenseehaus, Hamburg, Germany, ³Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, ⁴Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, ⁵Sanofi Aventis Deutschland GmbH, Berlin, Germany, ⁶GKM Gesellschaft für Therapieforschung, Munich, Germany, ⁷MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, ⁸Outpatient practice, Haldensleben, Germany, ⁹Outpatient practice, Ludwigslust, Germany, ¹⁰Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, ¹¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
Abstract Number: 0993 • ACR Convergence 2020
N-linked Glycosylation of the Immunoglobulin Variable Domain Affects Antigen Binding and Autoreactive B Cell Activation
Theresa Kissel¹, Changrong Ge², Lise Hafkenscheid¹, Linda Slot¹, Marco Cavallari³, Joanneke Kwekkeboom⁴, Manfred Wuhrer¹, Thomas Huizinga¹, Hans Scherer¹, Michael Reth³, Rikard Holmdahl² and René Toes¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Karolinska Institutet, Solna, Sweden, ³University Freiburg, Freiburg, Germany, ⁴Leiden Univeristy Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies, the hallmarking autoantibodies in Rheumatoid Arthritis (RA), are characterized by N-linked glycans in the variable domain (V-domain). The occurrence of these…
Abstract Number: 1013 • ACR Convergence 2020
National Burden of RA in Canada 1990-2017: Findings from the Global Burden of Disease Study 2017
Nejat Hassen¹, Diane Lacaille², Nizal Sarrafzadegan³, Alice Xu⁴, Sophia Sidi⁴, Amani Alandejani⁴, Marjan Mansourian⁵ and Jacek Kopec¹, ¹University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada, ²University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, ³Isfahan University of Medical Sciences, University of British Columbia, Isfahan, Esfahan, Iran, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Isfahan University of Medical Sciences, Isfahan, Iran
Background/Purpose: It is estimated that over 120,000 individuals currently have rheumatoid arthritis (RA) in Canada, yet a comprehensive study summarizing the epidemiology of RA burden…
Abstract Number: 1184 • ACR Convergence 2020
In a Prospective RA Cohort, Higher Baseline Disease Activity Is an Independent Predictor of Decline in Left Ventricular Diastolic Function
Elizabeth Park¹, Kazato Ito², Christopher Depender¹, Jon Giles¹ and Joan Bathon¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) patients are at nearly 50% increased risk of heart failure (HF) compared to non-RA patients, despite adjusting for the presence of…
Abstract Number: 1200 • ACR Convergence 2020
Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function
Tim Wilson¹, Joshua Solomon², Jeffrey Swigris², Erika Darrah³ and M Kristen Demoruelle¹, ¹University of Colorado, Denver, CO, ²National Jewish Health, Denver, CO, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) associated-interstitial lung disease (ILD) affects approximately 10% of RA patients. It is a leading cause of morbidity and mortality, which is…
Abstract Number: 1216 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
Rieke Alten¹, William F. C. Rigby², Alena Pechonkina³, Zhaoyu Yin⁴, Ken Hasegawa⁴, Thijs Hendrikx⁵, Tatsuya Atsumi⁶ and Rene Westhovens⁷, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Gilead Sciences, Inc., Foster City, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: In FINCH 3, filgotinib (FIL)—a potent, selective, oral JAK1 inhibitor1—in combination with methotrexate (MTX), demonstrated significant improvements in signs and symptoms of rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].